Aridis Pharmaceuticals (ARDS)
US Market

Aridis Pharmaceuticals Stock Analysis & Ratings

ARDS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.88 - $7.69
Previous Close$1.1
Average Volume (3M)100.06K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-0.3
Next EarningsAug 16, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart ScoreN/A



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Aridis Pharmaceuticals’s price range in the past 12 months?
Aridis Pharmaceuticals lowest stock price was $0.88 and its highest was $7.69 in the past 12 months.
    What is Aridis Pharmaceuticals’s market cap?
    Currently, no data Available
    What is Aridis Pharmaceuticals’s price target?
    The average price target for Aridis Pharmaceuticals is $19.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $19.00 ,the lowest forecast is $19.00. The average price target represents 1627.27% Increase from the current price of $1.1.
      What do analysts say about Aridis Pharmaceuticals?
      Aridis Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
        When is Aridis Pharmaceuticals’s upcoming earnings report date?
        Aridis Pharmaceuticals’s upcoming earnings report date is Aug 16, 2022 which is in 43 days.
          How were Aridis Pharmaceuticals’s earnings last quarter?
          Currently, no data Available
          Is Aridis Pharmaceuticals overvalued?
          According to Wall Street analysts Aridis Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Aridis Pharmaceuticals pay dividends?
            Aridis Pharmaceuticals does not currently pay dividends.
            What is Aridis Pharmaceuticals’s EPS estimate?
            Aridis Pharmaceuticals’s EPS estimate is -$0.06.
              How many shares outstanding does Aridis Pharmaceuticals have?
              Aridis Pharmaceuticals has 17,701,591 shares outstanding.
                What happened to Aridis Pharmaceuticals’s price movement after its last earnings report?
                Currently, no data Available
                Which hedge fund is a major shareholder of Aridis Pharmaceuticals?
                Currently, no hedge funds are holding shares in ARDS


                Aridis Pharmaceuticals Stock Analysis

                Smart Score
                Not Ranked
                Price Target
                ▲(1627.27% Upside)
                Moderate Buy
                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Aridis Pharmaceuticals

                Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.

                Similar Stocks
                Price & Change
                Crinetics Pharmaceuticals
                Entasis Therapeutics Holdings
                Eton Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis